CN1665511A - 促使吸烟者戒烟的方法 - Google Patents

促使吸烟者戒烟的方法 Download PDF

Info

Publication number
CN1665511A
CN1665511A CN038156369A CN03815636A CN1665511A CN 1665511 A CN1665511 A CN 1665511A CN 038156369 A CN038156369 A CN 038156369A CN 03815636 A CN03815636 A CN 03815636A CN 1665511 A CN1665511 A CN 1665511A
Authority
CN
China
Prior art keywords
purposes
smoking
reboxetine
officinal salt
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN038156369A
Other languages
English (en)
Chinese (zh)
Inventor
E·H·F·旺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of CN1665511A publication Critical patent/CN1665511A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN038156369A 2002-07-01 2003-06-26 促使吸烟者戒烟的方法 Pending CN1665511A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39289302P 2002-07-01 2002-07-01
US60/392,893 2002-07-01

Publications (1)

Publication Number Publication Date
CN1665511A true CN1665511A (zh) 2005-09-07

Family

ID=30000949

Family Applications (1)

Application Number Title Priority Date Filing Date
CN038156369A Pending CN1665511A (zh) 2002-07-01 2003-06-26 促使吸烟者戒烟的方法

Country Status (22)

Country Link
US (1) US20040102440A1 (fr)
EP (1) EP1534254A2 (fr)
JP (1) JP2005531631A (fr)
CN (1) CN1665511A (fr)
AP (1) AP2004003188A0 (fr)
AU (1) AU2003253609A1 (fr)
BR (1) BR0312293A (fr)
CA (1) CA2491549A1 (fr)
EA (1) EA200401584A1 (fr)
EC (1) ECSP045517A (fr)
HR (1) HRP20041194A2 (fr)
IL (1) IL165882A0 (fr)
IS (1) IS7600A (fr)
MA (1) MA27597A1 (fr)
MX (1) MXPA05000296A (fr)
NO (1) NO20045535L (fr)
OA (1) OA12878A (fr)
PL (1) PL373620A1 (fr)
RS (1) RS115204A (fr)
TN (1) TNSN04267A1 (fr)
WO (1) WO2004002463A2 (fr)
ZA (1) ZA200410339B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102573821A (zh) * 2009-09-30 2012-07-11 哈兰·克莱顿·比利 保持体重的戒烟法及营养补充剂
CN104381577A (zh) * 2014-11-18 2015-03-04 安徽润康保健食品有限公司 一种具有戒烟功能的口香糖

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
JP4708795B2 (ja) 2002-12-20 2011-06-22 ニコノヴァム エービー 物理的および化学的に安定なニコチン−含有粒状物質
EP1870096A3 (fr) * 2003-04-29 2011-04-20 Orexigen Therapeutics, Inc. Compositions pour influencer la perte de poids
PT2316456T (pt) 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
RU2408368C2 (ru) * 2005-06-27 2011-01-10 Биовэйл Лэборэториз Интернэшнл С.Р.Л. Препараты соли бупропиона с модифицированным высвобождением
JP5180092B2 (ja) 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
AU2007224584A1 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US20070297991A1 (en) * 2006-06-23 2007-12-27 Minu, L.L.C. Neural conduit agent dissemination for smoking cessation and other applications
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
US8685962B2 (en) * 2007-07-02 2014-04-01 Technion Research & Development Foundation Limited Compositions, articles and methods comprising TSPO ligands for preventing or reducing tobacco-associated damage
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20110046116A1 (en) * 2009-08-20 2011-02-24 Cukrowski Walter J Sedative for use during eye surgery
EP3659604A1 (fr) 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Méthodes d'amaigrissementu pour des patients souffrant d'une dépression sévère
US20130216513A1 (en) 2010-07-09 2013-08-22 Biogen Idec Hemophilia Inc. Chimeric Clotting Factors
HUE049859T2 (hu) 2012-06-06 2020-10-28 Nalpropion Pharmaceuticals Llc Készítmény magas kardiovaszkuláris kockázatnak kitett páciensekben túlsúly és elhízás kezelésére szolgáló eljárásban történõ alkalmazásra
WO2015054730A1 (fr) * 2013-10-14 2015-04-23 Palmaya Pty Ltd Compositions et procédés pour les administrer
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9909478A (pt) * 1998-04-09 2000-12-19 Upjohn Co Novos tratamentos para vários distúrbios do sistema nervoso
AU764579B2 (en) * 1998-05-08 2003-08-21 Pharmacia & Upjohn Company New drug combinations of a N.A.R.I., preferably reboxetine, and pindolol
ATE305307T1 (de) * 1999-07-01 2005-10-15 Pharmacia & Upjohn Co Llc Reboxetin zur behandlung von migränekopfschmerzen
DE10004547A1 (de) * 2000-02-02 2001-08-09 Liedtke Pharmed Gmbh Verfahren zur selektiven Verabreichung zentralnervös aktiver Stoffe

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102573821A (zh) * 2009-09-30 2012-07-11 哈兰·克莱顿·比利 保持体重的戒烟法及营养补充剂
CN104381577A (zh) * 2014-11-18 2015-03-04 安徽润康保健食品有限公司 一种具有戒烟功能的口香糖

Also Published As

Publication number Publication date
MXPA05000296A (es) 2005-08-19
IL165882A0 (en) 2006-01-15
IS7600A (is) 2004-12-16
ZA200410339B (en) 2006-07-26
WO2004002463A2 (fr) 2004-01-08
HRP20041194A2 (en) 2005-06-30
US20040102440A1 (en) 2004-05-27
JP2005531631A (ja) 2005-10-20
NO20045535L (no) 2005-01-27
TNSN04267A1 (fr) 2007-03-12
RS115204A (en) 2007-02-05
PL373620A1 (en) 2005-09-05
WO2004002463A3 (fr) 2004-02-19
ECSP045517A (es) 2005-03-10
MA27597A1 (fr) 2005-11-01
EP1534254A2 (fr) 2005-06-01
AP2004003188A0 (en) 2004-12-31
CA2491549A1 (fr) 2004-01-08
EA200401584A1 (ru) 2005-08-25
OA12878A (en) 2006-09-15
BR0312293A (pt) 2005-04-12
AU2003253609A1 (en) 2004-01-19

Similar Documents

Publication Publication Date Title
CN1665511A (zh) 促使吸烟者戒烟的方法
CN1155410C (zh) 治疗尼古丁成瘾的含有尼古丁受体拮抗剂和抗抑郁药或抗焦虑药的组合物
Teoh et al. Oral manifestations of illicit drug use
US6538034B2 (en) Methods of treating or preventing weight gain, obesity, and related disorders
US20020019421A1 (en) Compositions and therapy for substance addiction
TW200418475A (en) Treatment of pain with combinations of nalbuphine and other kappa-opioid receptor agonists and opioid receptor antagonists
HU225534B1 (en) Pharmaceutical compositions comprising mirtazapine and one or more selective serotonin reuptake inhibitors
TW200803901A (en) Methods of treating anxiety disorders
MXPA02001811A (es) Metodos de uso de inhibidores de la reabsorcion de la serotonina selectivos, de inicio rapido de accion para el tratamiento de la disfuncion sexual.
US20220339139A1 (en) Novel n,n-dimethyltryptamine compositions and methods
CN1520289A (zh) 延缓射精的方法
JP2005531612A (ja) ネフォパムの製剤および痛みの治療におけるその使用
JP2003176227A (ja) 製薬組成物、喫煙を控えている患者の喫煙禁断症状を軽減する方法及び患者の喫煙禁断症状を軽減するキット
US20100029771A1 (en) Treatment of addictive disorders
CN1384104A (zh) 使用吡咯衍生物的方法、试剂盒和组合物
US20040115263A1 (en) Use of bupropion for treating restless legs syndrome
EP1734940B1 (fr) Combinaisons de deramciclane et d'opioides destines a l'utilisation analgesique
US20220175755A1 (en) Methods of treating tobacco smoking addiction, and treating nicotine and tobacco smoking addiction
CA2338326A1 (fr) Procedes et compositions pour le traitement et la prevention des toxicomanies a l'aide de moclobemide
KR20220071297A (ko) 신경정신계 장애의 치료를 위한 조성물 및 방법
KR20050016679A (ko) 금연을 촉진시키는 방법
TW574037B (en) Nicotine addiction treatment
JP2007501245A (ja) メタボリックシンドロームを治療するための方法
CN1771029A (zh) 用于治疗酒精滥用的活性物质组合物及疗法
CN1931153A (zh) 用于治疗抑郁症及相关病症的包括文拉法辛的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1076736

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1076736

Country of ref document: HK